Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
종목 코드 MRVI
회사 이름Maravai LifeSciences Holdings Inc
상장일Nov 20, 2020
CEOMr. Bernd Brust
직원 수570
유형Ordinary Share
회계 연도 종료Nov 20
주소10770 Wateridge Circle Suite 200
도시SAN DIEGO
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호92121
전화18585460004
웹사이트https://www.maravai.com/
종목 코드 MRVI
상장일Nov 20, 2020
CEOMr. Bernd Brust
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음